Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Pharm Res. 2010 Apr 13;27(11):2317–2329. doi: 10.1007/s11095-010-0091-0

Fig. 5.

Fig. 5

Cell viability of nanoconjugate with LOEt: Effects on cell viability of TMZ, P/PEG(2%)/LOEt (40%) and P/PEG(2%)/LOEt (40%)/TMZH(17%) on a) U87MG and b) T98G cells. Nanoconjugate P/PEG(2%)/LOEt (40%) without drug was used as a control for the conjugate P/PEG (2%)/LOEt(40%)/TMZH(17%) with drug and contains equivalent amount of polymer backbone.